MedTrace Logo

Measurement of HTL0016878 in Cerebrospinal Fluid

NCT04849286 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2021-04-19

No results posted yet for this study

Summary

A Phase 1, open-label, randomised, single oral dose study to determine the concentration of HTL0016878 in CSF and plasma in healthy male subjects following dosing with HTL0016878 10 mg or 20 mg oral solution

Conditions

  • Healthy Subjects

Interventions

DRUG

HTL0016878

Oral solution

Sponsors & Collaborators

  • Nxera Pharma UK Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-09-26
Primary Completion
2018-12-07
Completion
2018-12-07

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04849286 on ClinicalTrials.gov